APAC Angina Pectoris Drugs Market

APAC Angina Pectoris Drugs Market Size (2024 to 2029)

The size of the Asia Pacific angina pectoris drugs market is forecasted to be growing at a healthy rate of 5.07% between 2024 to 2029.

The growing burden of lifestyle diseases in the aging population directly affects the socio-economic aspects of nations, requiring immediate action to limit and control them.

As a result, the APAC angina pectoris drugs market is primarily driven by the increasing prevalence of lifestyle-related diseases like obesity, cardiovascular disease, diabetes, hypertension, etc. It is estimated that over 15.8 million people suffer from angina pectoris each year, and up to 600,000 new cases are diagnosed each year. The prevalence of angina increases dramatically with age in both sexes, ranging from 2.5% to 5.2% in men aged 45 to 54 and from 10.3% to 20.2% in men 65 to 74 years old and between 0.15% and 1.2% of women aged 45- 54 and 10.9%. 15.3% among women aged 65 to 74. The ease of availability of therapeutic drugs for angina pectoris, the development of new drugs, and the increased awareness of various cardiovascular disorders are anticipated to drive this market growth during the forecast period.

The annual risk of associated non-fatal myocardial infarction (MI) and death is reported at 3.1% and 1.1-2.1%, respectively. Technological advances in personalized cardiovascular medicine and improvements in innovative drug delivery systems are other driving forces. Chronic stable angina affects 3-5% of the population in APAC countries, with an estimated annual risk of death and non-fatal myocardial infarction (MI) of 1-2%. The continuous development of new diagnostic tests and therapies for the treatment of angina is anticipated to provide potential growth opportunities for market growth.

However, factors such as low healthcare expenditure per capita and high cost of surgeries such as coronary artery bypass grafting are anticipated to limit the market growth during the forecast period. Moreover, a lack of reimbursement programs to cover the drug costs may challenge the market in specific APAC regional markets during the forecast period.

This research report on the APAC angina pectoris drugs market has been segmented & sub-segmented into the following categories

APAC Angina Pectoris Drugs Market  Analysis By Therapeutic Class

• Beta-Blockers     

• Calcium Antagonists      

• Anticoagulants    
• Anti-Platelets     
• Others    

APAC Angina Pectoris Drugs Market  Analysis By Country

• India

• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

The Chinese regional market is anticipated to experience significant growth during the forecast period in this region.

China offers an excellent opportunity for market expansion due to the easy availability of drugs, the ongoing health reform for Healthy China 2020, and the 12th Five-Year Plan support measures targeting biotechnology as a key development sector. In addition, the presence of a large target population and high unmet clinical needs are some of the factors that are anticipated to drive growth in this region. The CVD death rate in rural Chinese areas exceeded that of urban areas, and in 2017 the rate was 319.23 per 100,000 population in rural areas and 269.51 per 100 000 inhabitants in urban areas. In early 2010, the incidence was reported at 72.4% million non-smokers in China were exposed to second-hand smoke; this also hikes the prevalence rates in China.

The market for angina pectoris drugs in India is also anticipated to grow steadily due to the increasing prevalence of angina pectoris, high awareness of CVD, large patient base, and improved health infrastructure. However, the prevalence of angina decreased from 27.82% to 11.24% over five years in India, attributed to improving healthcare infrastructure and social reforms.

Other Asia-Pacific regions like Australia, Japan, South Korea, and Taiwan are anticipated to grow at a good rate due to a large target population, improving pharmaceutical companies, and significant unmet clinical needs.

KEY MARKET PLAYERS

Some of the major companies dominating the market by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd., and Baxter Healthcare Corporation.